iRegene’s NouvSight001 Cleared for Retinitis Pigmentosa Trials in China and U.S.
iRegene Therapeutics has secured regulatory clearance in both China and the United States to move NouvSight001, its off-the-shelf photoreceptor cell therapy, into clinical development for retinitis pigmentosa (RP), giving the company another opportunity to test whether its cell-replacement platform can translate across very different degenerative diseases.
The China-based regenerative medicine company announced on September 7 that the National Medical Products Administration (NMPA) has cleared NouvSight001 for a combined Phase I/III clinical study in patients with RP. The study will evaluate the therapy’s safety and tolerability while also looking for preliminary signs of efficacy. (Sohu)
At the same time, the U.S. Food and Drug Administration (FDA) has cleared a Phase I/II clinical study of NouvSight001 for the same indication and granted the program what iRegene describes as Special Exemption status. The parallel regulatory clearances establish a path for clinical development on both sides of the Pacific. (Sohu)
For iRegene, the milestone is important not simply because NouvSight001 is entering human testing, but because the program represents an expansion of the company’s regenerative-medicine platform from neurological diseases into ophthalmology.
Replacing photoreceptors rather than correcting a single mutation
NouvSight001 is a universal, allogeneic and off-the-shelf photoreceptor cell therapy developed using iRegene’s proprietary AI + chemical induction (AI + Chem) platform. The approach is intended to generate therapeutic cells from induced pluripotent stem cells (iPSCs) through controlled chemical differentiation.
That distinction could be particularly relevant in retinitis pigmentosa.
RP is not a single disease caused by one mutation. Rather, it encompasses a genetically diverse group of inherited retinal disorders in which photoreceptor cells progressively degenerate. Patients frequently first experience impaired night vision, followed by progressive loss of peripheral vision and, in advanced disease, severe visual impairment or blindness.
Because many different genes can cause RP, developing mutation-specific treatments for the entire patient population is challenging.
NouvSight001 takes a different approach. Instead of correcting a particular genetic defect, the therapy is designed as a cell-replacement treatment, supplying photoreceptor progenitor cells intended to replace or compensate for retinal cells lost during the disease process.
Importantly, iRegene says the treatment is not dependent on a patient’s specific disease-causing genotype. (Synapse)
If that concept proves clinically effective, it could potentially give a cell-replacement therapy a broader addressable population than treatments restricted to individual genetic subtypes of RP. That possibility, however, still needs to be demonstrated in controlled human studies.
FDA orphan designation already in place
NouvSight001 entered the regulatory spotlight well before the latest IND clearances.
The FDA granted the program Orphan Drug Designation on March 20, 2024, specifically for the treatment of retinitis pigmentosa. The FDA database identifies the therapy as human iPSC-derived photoreceptor progenitor cells, with iRegene Therapeutics listed as the sponsor. (FDA Access Data)
FDA Orphan Drug Designation record for NouvSight001
Orphan Drug Designation does not mean that FDA has approved the therapy for use in patients outside clinical studies. Rather, it provides regulatory and development incentives for therapies targeting rare diseases. FDA’s database currently lists NouvSight001 as designated but not approved for the orphan indication. (FDA Access Data)
The new FDA clinical clearance therefore represents the next meaningful step: moving the program from regulatory preparation toward direct evaluation in patients.
An increasingly broad iPSC cell-therapy pipeline
NouvSight001 also provides another test of whether iRegene’s manufacturing and differentiation technology can function as a repeatable platform rather than a single-product technology.
The company’s pipeline already includes several iPSC-derived cell therapies targeting neurological diseases.
Its most advanced program, NouvNeu001, is being developed for Parkinson’s disease, while NouvNeu003 targets early-onset Parkinson’s disease and NouvNeu004 is being developed for multiple system atrophy. iRegene’s current pipeline also includes NouvNeu002 for ischemic stroke. (Iregene)
iRegene Therapeutics official website and pipeline
The common thread is iRegene’s effort to manufacture standardized therapeutic cells through its AI- and chemistry-assisted differentiation platform.
For cell therapies, that manufacturing question is critical. Personalized cell products can require complicated patient-specific collection, manufacturing and logistics. A genuinely scalable allogeneic product manufactured in advance could offer a substantially different commercial model.
With NouvSight001, iRegene is attempting to apply that model to the retina.
Why the NouvSight001 program matters
The scientific rationale behind retinal cell replacement is compelling: the eye is a relatively contained organ, photoreceptor loss is central to the pathology of RP, and retinal structure can be evaluated using sophisticated imaging and functional tests.
The difficult part is translating that biological logic into meaningful vision improvement.
The upcoming trials will therefore need to answer several fundamental questions: whether transplanted photoreceptor progenitor cells survive in the human retina, whether they integrate or otherwise restore useful retinal function, how durable any benefit may be, and whether transplantation can be performed with an acceptable safety profile.
Those questions become especially important as development advances beyond an initial safety study.
Still, securing clinical clearance from regulators in both China and the United States gives iRegene an unusually broad development framework for an early-stage ophthalmic cell therapy. It also provides an opportunity to generate clinical evidence across different patient populations and regulatory environments.
For RP patients, the attraction of NouvSight001 is straightforward. Rather than designing a separate therapy for each disease-causing mutation, iRegene is trying to develop a ready-made source of replacement photoreceptor cells that could potentially be used across multiple genetic forms of the disease.
Whether that promise translates into restored or preserved vision will now be put to the clinical test.
References
- iRegene Therapeutics. “Innovative ophthalmic product receives dual China-U.S. IND clearances.” September 7, 2026.
iRegene Therapeutics official website - U.S. Food and Drug Administration. Orphan Drug Designation database — human iPSC-derived photoreceptor progenitor cells for retinitis pigmentosa, designated March 20, 2024.
FDA NouvSight001 Orphan Drug Designation record - eMedClub. “Innovative ophthalmic product receives China and U.S. IND approvals, further validating iRegene’s pipeline.” September 7, 2026.
eMedClub report on NouvSight001 - iRegene Therapeutics. Corporate pipeline and AI + Chem technology platform.
iRegene Therapeutics - VCBeat Health. “Dual IND Approvals in China and the US! Off-the-Shelf Cell Therapy Breaks the Deadlock in Ophthalmic Treatment.” September 8, 2026.
VCBeat Health coverage
